| Message: | The Development of PT-141:
PT-141 was developed from the Melanotan 2 Peptide, which underwent testing as a sunless tanning agent. In initial testing, Melanotan 2 did induce tanning, but additionally caused sexual arousal and spontaneous erections as unexpected side effects in nine out of the ten original male volunteer test subjects. Palatin completed patient treatment in its Phase 2B clinical trial in premenopausal women with FSD Primary data analysis and announcement of top-line results anticipated in first-half of fourth quarter of calendar year 2012. In studies, PT-141 was shown to be effective in treating sexual dysfunction in both men (erectile dysfunction or impotence) and women (sexual arousal disorder). Unlike Viagra and other related medications, it does not act upon the vascular system, but directly increases sexual desire via the nervous system.
Application:
PT-141 functions by activating the melanocortin receptor and MC4R namely. Bremelanotide originally was tested for nasal spray delivery but was discontinued after concerns about side effects. Bremelanotide PT141, as Melanotan II, may cause spontaneous arousal enhancing effect. Unlike other supplements, PT-141 results do not act on the vascular body, but directly increases desires through the nervous system . |
my account
